Detalhe da pesquisa
1.
Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force.
Ann Oncol
; 25(8): 1492-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24569913
2.
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Ann Oncol
; 20(11): 1867-73, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19541792
3.
Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin.
J Natl Cancer Inst
; 80(11): 864-8, 1988 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-3392746
4.
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
J Natl Cancer Inst
; 85(14): 1154-9, 1993 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-8320744
5.
Phase I study of recombinant beta-interferon given by four-hour infusion.
Cancer Res
; 47(4): 1174-8, 1987 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-3802098
6.
Staphylococcal Protein A column: correlation of mitogenicity of perfused plasma with clinical response.
Cancer Res
; 45(9): 4486-94, 1985 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-4028030
7.
Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
J Clin Oncol
; 7(8): 1137-41, 1989 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-2526864
8.
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
J Clin Oncol
; 12(10): 2204-10, 1994 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-7931490
9.
Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
J Clin Oncol
; 5(2): 286-91, 1987 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-3543247
10.
Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
J Clin Oncol
; 11(8): 1598-601, 1993 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-8393099
11.
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
J Clin Oncol
; 15(1): 103-9, 1997 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-8996130
12.
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
J Clin Oncol
; 2(7): 782-7, 1984 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-6539812
13.
A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer.
J Clin Oncol
; 2(9): 1012-6, 1984 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-6470752
14.
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
J Clin Oncol
; 12(5): 1045-9, 1994 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-8164028
15.
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
J Clin Oncol
; 11(5): 873-8, 1993 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-8387576
16.
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
Ann Oncol
; 21 Suppl 5: v232-43, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20555089
17.
Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens.
Blood Rev
; 3(4): 216-21, 1989 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-2692744
18.
Potential for combination therapy with the new antiserotonergic agents.
Eur J Cancer
; 29A Suppl 1: S39-41, 1993.
Artigo
em Inglês
| MEDLINE | ID: mdl-8427725
19.
Correlation of anti-emetic efficacy and plasma levels of ondansetron.
Eur J Cancer
; 26(8): 879-82, 1990.
Artigo
em Inglês
| MEDLINE | ID: mdl-2145930
20.
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Eur J Cancer
; 39(10): 1395-401, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12826042